KR102647026B1 - 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 - Google Patents

플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 Download PDF

Info

Publication number
KR102647026B1
KR102647026B1 KR1020177026258A KR20177026258A KR102647026B1 KR 102647026 B1 KR102647026 B1 KR 102647026B1 KR 1020177026258 A KR1020177026258 A KR 1020177026258A KR 20177026258 A KR20177026258 A KR 20177026258A KR 102647026 B1 KR102647026 B1 KR 102647026B1
Authority
KR
South Korea
Prior art keywords
fold
compound
delete delete
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177026258A
Other languages
English (en)
Korean (ko)
Other versions
KR20170117578A (ko
Inventor
벤 씨. 어스큐
다케루 후루야
Original Assignee
사이플루어 라이프 사이언시즈, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이플루어 라이프 사이언시즈, 인크 filed Critical 사이플루어 라이프 사이언시즈, 인크
Publication of KR20170117578A publication Critical patent/KR20170117578A/ko
Application granted granted Critical
Publication of KR102647026B1 publication Critical patent/KR102647026B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177026258A 2015-02-19 2016-02-19 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도 Active KR102647026B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118303P 2015-02-19 2015-02-19
US62/118,303 2015-02-19
PCT/US2016/018612 WO2016134223A2 (en) 2015-02-19 2016-02-19 Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof

Publications (2)

Publication Number Publication Date
KR20170117578A KR20170117578A (ko) 2017-10-23
KR102647026B1 true KR102647026B1 (ko) 2024-03-12

Family

ID=56689184

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026258A Active KR102647026B1 (ko) 2015-02-19 2016-02-19 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도

Country Status (13)

Country Link
US (5) US9790222B2 (enExample)
EP (2) EP3259271B1 (enExample)
JP (2) JP2018510139A (enExample)
KR (1) KR102647026B1 (enExample)
CN (2) CN114805342A (enExample)
AU (1) AU2016219906B2 (enExample)
BR (1) BR112017017888A2 (enExample)
CA (1) CA2976634C (enExample)
ES (1) ES2892954T3 (enExample)
IL (1) IL253873A0 (enExample)
RU (1) RU2017132433A (enExample)
TW (1) TWI736529B (enExample)
WO (1) WO2016134223A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2953948T3 (en) 2013-02-07 2017-12-18 Scifluor Life Sciences Inc FLUORINATED INTEGRIN ANTAGONISTS
US8901144B2 (en) * 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN114805342A (zh) * 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
WO2016154369A1 (en) * 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Composition and methods for treating chronic kidney disease
AU2016255494A1 (en) * 2015-04-30 2017-11-02 Scifluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
WO2017189828A1 (en) 2016-04-27 2017-11-02 Scifluor Life Sciences, Inc. Nonanoic and decanoic acid derivatives and uses thereof
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
ES2886650T3 (es) 2016-11-08 2021-12-20 Bristol Myers Squibb Co Derivados de indazol como antagonistas de integrina alfaV
WO2018089360A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
EP3538527B1 (en) 2016-11-08 2021-10-13 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
TW201819378A (zh) * 2016-11-08 2018-06-01 美商必治妥美雅史谷比公司 作為αｖ整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物
EP3538525B1 (en) 2016-11-08 2022-06-22 Bristol-Myers Squibb Company 3-substituted propionic acids as alpha v integrin inhibitors
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
TW201835078A (zh) 2017-02-28 2018-10-01 美商萊築理公司 αvβ6整合蛋白之抑制劑
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds
SG11202004077WA (en) 2017-11-07 2020-05-28 Bristol Myers Squibb Co Pyrrolopyrazine derivatives as alpha v integrin inhibitors
AU2019260738B2 (en) * 2018-04-27 2025-01-30 Arrowhead Pharmaceuticals, Inc. Integrin targeting ligands and uses thereof
MX2021002181A (es) 2018-08-29 2021-07-15 Morphic Therapeutic Inc Inhibicion de la integrina alfa v beta 6.
TWI835840B (zh) * 2018-08-29 2024-03-21 美商莫菲克醫療股份有限公司 αvβ6整合素之抑制劑
MX2022013753A (es) * 2020-05-07 2023-01-30 Pliant Therapeutics Inc Tratamiento de enfermedades respiratorias con compuestos de aminoacidos.
WO2021231581A1 (en) 2020-05-12 2021-11-18 Scifluor Life Sciences, Inc. METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED α V INTEGRIN ANTAGONISTS
EP4232079A4 (en) * 2020-10-20 2024-10-23 The Board Of Trustees Of The Leland Stanford Junior University INJECTABLE HYDROGELS FOR ADOPTIVE CELL THERAPY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500326A (ja) 1999-06-02 2004-01-08 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
JP2004508401A (ja) 2000-09-18 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シクロオキシゲナーゼ−２阻害剤およびインテグリンアルファ−ｖアンタゴニストの組合せを用いる炎症の治療
JP2007507440A (ja) * 2003-10-01 2007-03-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
WO2014124302A1 (en) * 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307483A4 (en) 1987-03-30 1990-02-06 Anritsu Corp LIGHT SIGNAL GENERATOR AND CALIBRATION METHOD OF A LIGHT POWER MEASURING DEVICE WITH THIS LIGHT SIGNAL GENERATOR.
CA1318254C (en) 1988-01-06 1993-05-25 Munehiro Tomikawa Inhibitory agent of hepatic fibrosis containing pantethine
EP0581904B1 (en) 1991-04-01 1997-05-28 Duke University Method of inhibiting fibrosis
US5501969A (en) 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
JP3818322B2 (ja) 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
US5736357A (en) 1994-10-27 1998-04-07 Arris Pharmaceutical Cathespin O protease
US6544767B1 (en) 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US5645839A (en) 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US6211184B1 (en) 1996-08-29 2001-04-03 Merck & Co., Inc. Integrin antagonists
WO1998008528A1 (en) 1996-08-30 1998-03-05 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
EA002822B1 (ru) 1997-12-17 2002-10-31 Мерк Энд Ко., Инк. Антагонисты рецептора интегрина
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
KR20030048081A (ko) * 1997-12-17 2003-06-18 머크 앤드 캄파니 인코포레이티드 인테그린 수용체 길항제를 포함하는 약제학적 조성물
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
WO1999030709A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
CN1284955A (zh) 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6117445A (en) 1998-01-28 2000-09-12 Link Technology Inc. Methods for the prevention and treatment of fibrosis and sclerosis
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6420396B1 (en) * 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
US6407241B1 (en) 1999-11-08 2002-06-18 Merck & Co., Inc. Process and intermediates for the preparation of imidazolidinone αv integrin antagonists
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
CA2397194C (en) 2000-01-20 2011-05-17 Mark E. Duggan Alpha v integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
WO2001062292A1 (en) 2000-02-22 2001-08-30 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
GB0011817D0 (en) * 2000-05-16 2000-07-05 Pharmacia & Upjohn Spa Antagonists of integrin receptors
ATE353219T1 (de) 2000-07-26 2007-02-15 Merck & Co Inc Alpha v integrin-rezeptor-antagonisten
JP2004509123A (ja) 2000-09-14 2004-03-25 メルク　エンド　カムパニー　インコーポレーテッド アルファνインテグリン受容体アンタゴニスト
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
CA2465416A1 (en) 2001-11-06 2003-05-15 Merck & Co., Inc. Amine salts of an integrin receptor antagonist
US20040053968A1 (en) 2001-12-28 2004-03-18 Hartman George D. Methods and compositions for treating peridontal disease
WO2004026233A2 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Mannitol formulation for integrin receptor antagonist
CA2507699A1 (en) 2002-12-20 2004-07-15 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
EP3673922A1 (en) * 2008-03-14 2020-07-01 VisEn Medical, Inc. Integrin targeting agents and methods of using same
WO2011060395A1 (en) 2009-11-16 2011-05-19 Schering Corporation Cyclic ureas useful as hiv inhibitors
NZ603789A (en) 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
ES2820855T3 (es) 2011-05-09 2021-04-22 Allegro Pharmaceuticals Llc Antagonistas del receptor de integrina y sus métodos de uso
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
CN114805342A (zh) 2015-02-19 2022-07-29 赛弗卢尔生命科学公司 氟化四氢萘啶基壬酸衍生物及其用途
AU2016255494A1 (en) 2015-04-30 2017-11-02 Scifluor Life Sciences, Inc. Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof
WO2018183795A1 (en) 2017-03-30 2018-10-04 Scifluor Life Sciences, Inc. Method of making tetrahydronaphthyridinyl nonanoic acid compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500326A (ja) 1999-06-02 2004-01-08 メルク　エンド　カムパニー　インコーポレーテッド αｖインテグリン受容体拮抗薬
JP2004508401A (ja) 2000-09-18 2004-03-18 メルク　エンド　カムパニー　インコーポレーテッド シクロオキシゲナーゼ−２阻害剤およびインテグリンアルファ−ｖアンタゴニストの組合せを用いる炎症の治療
JP2007507440A (ja) * 2003-10-01 2007-03-29 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗線維症薬としてのαｖβ３及びαｖβ６インテグリンアンタゴニスト
WO2014124302A1 (en) * 2013-02-07 2014-08-14 Scifluor Life Sciences, Llc Fluorinated integrin antagonists

Also Published As

Publication number Publication date
EP3259271A2 (en) 2017-12-27
CN107531699A (zh) 2018-01-02
TW201643161A (zh) 2016-12-16
EP3259271A4 (en) 2018-07-11
US20210277000A1 (en) 2021-09-09
BR112017017888A2 (pt) 2018-04-10
US10301307B2 (en) 2019-05-28
EP3259271B1 (en) 2021-05-05
IL253873A0 (en) 2017-10-31
US9790222B2 (en) 2017-10-17
CN114805342A (zh) 2022-07-29
US20190225609A1 (en) 2019-07-25
US20160244447A1 (en) 2016-08-25
KR20170117578A (ko) 2017-10-23
US11685738B2 (en) 2023-06-27
WO2016134223A3 (en) 2016-10-20
WO2016134223A2 (en) 2016-08-25
EP3925959A1 (en) 2021-12-22
JP2018510139A (ja) 2018-04-12
CA2976634C (en) 2023-10-17
RU2017132433A3 (enExample) 2019-03-25
AU2016219906B2 (en) 2020-10-01
US20170369490A1 (en) 2017-12-28
TWI736529B (zh) 2021-08-21
RU2017132433A (ru) 2019-03-19
ES2892954T3 (es) 2022-02-07
JP7191299B2 (ja) 2022-12-19
CA2976634A1 (en) 2016-08-25
AU2016219906A1 (en) 2017-09-07
US20240092775A1 (en) 2024-03-21
US12286432B2 (en) 2025-04-29
JP2021008511A (ja) 2021-01-28

Similar Documents

Publication Publication Date Title
KR102647026B1 (ko) 플루오르화 테트라히드로나프티리디닐 노난산 유도체 및 이의 용도
US10106537B2 (en) Fluorinated integrin antagonists
US10118929B2 (en) Nonanoic and decanoic acid derivatives and uses thereof
HK40066388A (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1241361B (en) Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
HK1243061A1 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
HK1248677B (en) Fluorinated integrin antagonists
HK1217696B (en) Fluorinated integrin antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170918

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210219

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230110

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231208

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240308

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240308

End annual number: 3

Start annual number: 1

PG1601 Publication of registration